

# UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS FO. Box 1430 Alexandra, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR STALEY A. BROD	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
08/844,731 27851	7590	04/21/1997		D5716-CIP3	18	
BENJAMIN 8011 CANDI			EXAMINER			
HOUSTON,				SAYALA, CHHAYA D		
				ART UNIT	PAPER NUMBER	
			•	1761		
				DATE MAILED: 07/31/2003		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)
	p.	08/844,731	BROD, STALEY A.
	Offic Action Summary	Examiner	Art Unit
	•	C. SAYALA	1761
	The MAILING DATE of this communication ap		i i
Period fo			
THE   - External after - If the - If NC - Failu - Any i	ORTENED STATUTORY PERIOD FOR REPL MAILING DATE OF THIS COMMUNICATION. Insions of time may be available under the provisions of 37 CFR 1. SIX (6) MONTHS from the mailing date of this communication. It is period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period re to reply within the set or extended period for reply will, by statut reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, not within the statutory minimum will apply and will expire SIX (6 te. cause the application to become	nay a reply be timely filed  of thirty (30) days will be considered timely. ) MONTHS from the mailing date of this communication.  me ABANDONED (35 U.S.C. \$ 133)
1)🛛	Responsive to communication(s) filed on am	endment and disclaim	er filed 6/20/03
2a)□		his action is non-final.	
3)	Since this application is in condition for allow		I matters prosecution as to the morite is
. –	closed in accordance with the practice under on of Claims	Ex parte Quayle, 193	5 C.D. 11, 453 O.G. 213.
4)🛛	Claim(s) 8-11 and 16-18 is/are pending in the	e application.	
,	4a) Of the above claim(s) is/are withdra	wn from consideration	
5)[	Claim(s) is/are allowed.		
6)⊠	Claim(s) 8-11 and 16-18 is/are rejected.	•	
7)	Claim(s) is/are objected to.		
	Claim(s) are subject to restriction and/o	or election requirement	t.
9)[	The specification is objected to by the Examine	er.	
10)[] 7	The drawing(s) filed on is/are: a)□ acce	pted or b) objected to	by the Examiner.
	Applicant may not request that any objection to the	ne drawing(s) be held in a	abeyance. See 37 CFR 1.85(a).
11) 🔲 🛚	The proposed drawing correction filed on	_ is: a)∏ approved b)	disapproved by the Examiner.
_	If approved, corrected drawings are required in re	•	
12)[] 7	The oath or declaration is objected to by the Ex	kaminer.	
riority u	nder 35 U.S.C. §§ 119 and 120		
13)	Acknowledgment is made of a claim for foreign	n priority under 35 U.S	.C. § 119(a)-(d) or (f).
a)[	☐ All b)☐ Some * c)☐ None of:		•
	1. Certified copies of the priority document	s have been received.	
	<ol><li>Certified copies of the priority document</li></ol>	s have been received	in Application No
	<ol> <li>Copies of the certified copies of the prio application from the International Bu ee the attached detailed Office action for a list</li> </ol>	reau (PCT Rule 17.2(a	a)).
	cknowledgment is made of a claim for domesti		
a) 15)∐ A	☐ The translation of the foreign language procknowledgment is made of a claim for domest	ovisional application ha	as been received.
ttachment	•		
) Notice ) Notice Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	Tur' 5) Notice	riew Summary (PTO-413) Paper No(s) e of Informal Patent Application (PTO-152) :
Patent and Tra D-326 (Rev	T. T.	tion Summary	Part of Paper No. 18

Application/Control Number: 08/844,731

Art Unit: 1761

### **DETAILED ACTION**

# Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) and the Intellectual Property and High Technology Technical Amendments Act of 2002 do not apply when the reference is a U.S. patent resulting directly or indirectly from an international application filed before November 29, 2000. Therefore, the prior art date of the reference is determined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

2. Claims 8-10, 16-18 are rejected under 35 U.S.C. 102(e) as being anticipated by Sobel (US Patent 5780021).

Sobel describes a method of treating or preventing diabetes (col. 1), which inherently would reduce blood glucose, with Type I interferon using the same dosages. See claims 1-2, 4 and col. 4, lines 10+ and col. 13, lines 10-30 that particularly describes oral administration.

Art Unit: 1761

# Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 8-11, 16-18 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sobel and Cummins, Jr.

Sobel teaches all of the limitations of the claims listed and discussed in paragraph 2 above. The patentee does not teach alternate day dosing. Cummins also teaches all of the limitations of the claims except the alternate day dosing. However, he does show that a daily dosage is possible, as a single dosage or as divided and administered in a multiple daily dose regimen. The reference also teaches a staggered regimen of 1-3 days per week or month as an alternative to daily dosing. See col. 5, lines 50-55. With such a flexibility as taught by the reference, and since it is common knowledge in the art to employ such a regimen instead of continuous dosing, for a variety of reasons such as, toxicity, the condition of the patient, patient reaction and amelioration of the disease condition, etc., it would have been obvious to one of ordinary skill in the art to adopt an alternate day dosing and administer IFN as shown by Cummins. It is worthwhile to note that even though Sobel teaches the same amounts, patentee states that the precise amount will depend on the judgement of the attending physician based on considerations of age, weight and condition of the patient.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. SAYALA at Group 1761, telephone number (703) 308-3035.

The fax phone number for the organization where this application or proceeding is assigned is (703) 305-3599.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is 703-308-0661.

C. SAYALA

**Primary Examiner** 

Group 1700.